Specialized medical AI models learn real-world clinical data despite their messiness. Our models extend to include flow cytometry, EEG, and ‑omics in a way that is invariant to how the data was acquired — without pre-calibration. This means we can handle missing data and causal biases, helping predict which patients will respond to specific treatments.
Dr. Roland Tegeder
Hologen AI
Hologen AI is a clinical-stage artificial intelligence company pioneering the use of Large Medicine Models (LMMs) — large-scale, multi-modal generative models — to optimize drug development, particularly in late-stage clinical trials.
Unlike most AI pharma companies focused on early discovery, Hologen improves trial design by reducing patient enrollment, shortening timelines, and increasing statistical power. Its platform integrates messy real-world data—such as brain scans, genomics, and clinical records—into a unified framework, enabling deep phenotyping and precise covariate adjustment. This allows for more accurate detection and characterization of treatment effects in complex diseases like Parkinson’s.
Hologen’s technology is currently being deployed on a Phase 3–ready Parkinson’s gene therapy asset, with the potential to cut patient requirements in half and significantly accelerate time to approval. By combining proprietary clinical data from millions of patients with advanced AI modeling, Hologen aims to set a new standard for how trials are run, making them faster, more efficient, and more likely to succeed.
Recent Insights
